Background The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a reliable outcome measure for cutaneous lupus erythematosus (CLE) in adults used in clinical trials. However, it has not been validated in children, limiting clinical trials for paediatric CLE. Objectives This study aimed to validate the CLASI in paediatrics. Methods Eleven paediatric patients with CLE, six dermatologists and six rheumatologists participated. The physicians were trained to use the CLASI and Physician's Global Assessment (PGA), and individually rated all patients using both tools. Each physician reassessed two randomly selected patients. Within each physician group, the intraclass correlation coefficient (ICC) was calculated to assess the reliability of each measure. Results CLASI activity scores demonstrated excellent inter-and intrarater reliability (ICC > 0Á90), while the PGA activity scores had good inter-rater reliability (ICC 0Á73-0Á77) among both specialties. PGA activity scores showed excellent (ICC 0Á89) and good intrarater reliability (ICC 0Á76) for dermatologists and rheumatologists, respectively. Limitations of this study include the small sample size of patients and potential recall bias during the physician rerating session. Conclusions CLASI activity measurement showed excellent inter-and intrarater reliability in paediatric CLE and superiority over the PGA. These results demonstrate that the CLASI is a reliable and valid outcome instrument for paediatric CLE.
Summary
Background The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a reliable outcome measure for cutaneous lupus erythematosus (CLE) in adults used in clinical trials. However, it has not been validated in children, limiting clinical trials for paediatric CLE. Objectives This study aimed to validate the CLASI in paediatrics. Methods Eleven paediatric patients with CLE, six dermatologists and six rheumatologists participated. The physicians were trained to use the CLASI and Physician's Global Assessment (PGA), and individually rated all patients using both tools. Each physician reassessed two randomly selected patients. Within each physician group, the intraclass correlation coefficient (ICC) was calculated to assess the reliability of each measure. Results CLASI activity scores demonstrated excellent inter-and intrarater reliability (ICC > 0Á90), while the PGA activity scores had good inter-rater reliability (ICC 0Á73-0Á77) among both specialties. PGA activity scores showed excellent (ICC 0Á89) and good intrarater reliability (ICC 0Á76) for dermatologists and rheumatologists, respectively. Limitations of this study include the small sample size of patients and potential recall bias during the physician rerating session. Conclusions CLASI activity measurement showed excellent inter-and intrarater reliability in paediatric CLE and superiority over the PGA. These results demonstrate that the CLASI is a reliable and valid outcome instrument for paediatric CLE.
What's already known about this topic?
• The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) has been established as a reliable outcome measure for CLE in adults and is used in clinical trials.
What does this study add?
• This study validates the reliability of the CLASI in the paediatric population with CLE, which can manifest differently from CLE in adults.
• This validation will allow clinical trials to assess treatment efficacy reliably in CLE.
Cutaneous lupus erythematosus (CLE) refers to skin manifestations of the autoimmune disease lupus erythematosus. Skin involvement is one of the most common presenting signs of systemic lupus erythematosus (SLE), and dermatological evaluation is critical to diagnose and monitor disease progression. 1 Patients may also present with isolated CLE without systemic disease. CLE can be disfiguring and distressing to patients. While lupus has been extensively researched in the adult population, few studies exist in the paediatric population. 2 The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated outcome measure for CLE in adults, 1, 3 and is designed to capture disease activity and damage in multiple subtypes of CLE including discoid lupus erythematosus, subacute CLE and acute CLE. 4 There are a number of new therapies being used in patients with CLE, but a validated assessment tool is necessary to measure outcomes reliably in clinical studies. Without a validated outcome measure, it is difficult to assess improvement in disease, making it challenging for new therapies to be approved. 4 A validated outcome measure also helps standardize patient care. 5 There have been numerous adult international studies using the CLASI that have demonstrated positive outcomes. [6] [7] [8] [9] While the CLASI has been validated in the adult population, no studies have been conducted to validate it in the paediatric population. The CLASI scores CLE on disease activity and skin damage measured in multiple anatomical locations. The activity score is divided into 'erythema' and 'scale/hypertrophy', and the damage score is measured by assessing 'dyspigmentation' and 'scarring/atrophy/panniculitis'. The CLASI also takes into account mucous membrane involvement and alopecia. The activity scores are easily tallied up through simple addition, whereas the 'dyspigmentation' section is doubled if the symptoms are present for longer than 12 months, and then added to the remaining damage sections (Fig. 1) . 1 Separation of the activity and damage scores is critical to assessing outcomes in autoimmune skin disease, as disease activity often improves with therapy, while long-term damage may not. Our study assessed the reliability and validity of the CLASI in the paediatric population with lupus to facilitate its use as a quantitative outcome measure in clinical trials. Additionally, we compared the ability of paediatric dermatologists and rheumatologists to use this instrument in the assessment of paediatric CLE.
Patients and methods
This study was approved by the University of Pennsylvania institutional review board. Eleven patients with paediatric CLE were evaluated at the autoimmune skin disease clinic at the University of Pennsylvania on a single day in March 2018. All 12 physicians and 11 patients gave consent before inclusion in the study. Patients aged 7-11 years gave oral assent, and patients aged 12-17 provided written assent. All physicians first completed a 45-min training session on the assessment of CLE using both the CLASI and skin Physician's Global Assessment (PGA) tools. This session included a review of CLE lesions to help ensure that the physicians were well prepared for reliably distinguishing between CLE and various other skin conditions that could exist in this patient population, such as acne or rosacea.
After the training, the physicians individually rated each patient using both measurement tools, in no particular order. Both the CLASI and PGA assessment tools generated two scores, one for activity and one for damage. Each score was analysed separately. Following completion of all 11 patient assessments using both the CLASI and PGA, the physicians were instructed to reassess two patients. At the end of the study activities, each physician completed a brief physician exit survey.
Physicians
Six dermatologists and six rheumatologists, all with experience in diagnosing and managing CLE, participated in this study. There were four academic-based fellowship-trained paediatric dermatologists, one paediatric dermatology fellow and one autoimmune dermatology fellow, as well as five academicbased fellowship-trained paediatric rheumatologists and one paediatric rheumatology fellow. The physicians were instructed to examine the patients based on availability with no predetermined order.
Patient participants
The study patients (10 female, one male) had clinical and/or pathological evidence consistent with the diagnosis of CLE, as well as evidence of active skin disease. No patient had any concomitant skin condition, such as active acne or rosacea.
Skin Physician's Global Assessment
The skin PGA is a tool that estimates overall skin disease severity and has been used in multiple validation studies for skin diseases. [10] [11] [12] [13] [14] [15] It requires physicians to score the patient's skinrelated health on a 0-10 scale (0 = worst skin condition imaginable, 10 = perfect health) for his or her overall skin The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI). The CLASI is an outcome measure used to assess skin disease in patients with lupus. Skin is assessed using two separate scores: one for skin activity (erythema and scale/hypertrophy) and one for skin damage (dyspigmentation, scarring/atrophy/panniculitis).
score, skin activity and skin damage. It also asks the physician to rate the patient's overall skin condition as mild, moderate or severe. The PGA was used to determine construct validity in this study.
Assessment of inter-and intrarater reliability
Inter-rater reliability was assessed among the dermatologists and the rheumatologists separately and together. Each physician evaluated all 11 patients during the study session. To assess intrarater reliability, all 12 physicians scored two randomly selected patients a second time. In order to minimize recall bias, the physicians were not informed that they would need to reassess two patients until after they had completed the initial assessment.
Statistical analysis
Within each physician group (dermatologists and rheumatologists) we estimated the intrarater reliability of each of the four scores (CLASI and PGA, activity and damage) using the intraclass correlation coefficient (ICC), calculated from a oneway ANOVA model. 16, 17 All repeated assessments from the same patient and the same physician were included in the analysis. Paired scores for a physician-patient combination were considered to follow the same normal distribution. Previous studies have determined an ICC of 0Á50-0Á70 as moderate, 0Á70-0Á81 as good and > 0Á81 as almost perfect. 3, 18 For this study, we considered ICC scores of 0Á50-0Á70 as moderate, 0Á70-0Á81 as good and > 0Á81 as excellent. We designated any ICC scores < 0Á5 as poor.
Within each physician group, we also estimated inter-rater ICC, calculated from a two-way ANOVA model where both the patients and physicians were considered as being randomly chosen from a large pool and treated as random effects. In cases where a patient was assessed twice by the same physician, only the first assessment was included in this analysis.
We assessed construct validity by estimating the change in skin PGA activity per unit change in the CLASI activity score and by estimating the change in skin PGA damage per unit change in the CLASI damage score, using a linear mixed model adjusted for within-physician and within-patient correlation (as random effects). We considered P-values < 0Á05 to be statistically significant for all analyses. The statistical analysis was carried out using R2Á15Á3 (www.r-project.org).
Results
The patient characteristics are described in Table 1 . Subtypes of CLE included discoid lupus erythematosus (n = 4), acute CLE (n = 4), tumid lupus erythematosus (n = 2) and subacute CLE (n = 1). The rating session took approximately 90 min for the 12 physicians to score the 11 patients using both the CLASI and PGA. Of the 55 categories that receive a score in the CLASI, with 29 categories being 'activity' and 26 being 'damage', all categories were present in our patient population (receiving a score of ≥ 1 by at least one physician), except for the damage score of 'scarring/atrophy/panniculitis' of the abdomen. However, the abdomen damage score for dyspigmentation was present (Fig. 1) .
Skin-assessment score among specialists
The mean and SD scores per patient separated by physician specialty for CLASI and PGA activity and damage scores are shown in Figure 2 . For the CLASI activity scores, variance between physician groups was 1Á56 and variance within physician groups was 0Á09. For the PGA activity scores, variance between physician groups was 0Á18 and variance within groups was 0Á003. For the CLASI damage scores, betweengroup variance was 2Á5 9 10 À14 and within-group variance was 4Á1 9 10 À16 . For the PGA damage scores, between-group variance was 0Á41 and within-group variance was 0Á01. All within-group variances were much smaller than the betweengroup variances, suggesting that the difference in scores was due to the two specialties, not individual physicians within each specialty.
Inter-rater reliability
The CLASI inter-rater reliability scores are summarized in Table 2 . The CLASI activity scores demonstrated excellent inter-rater reliability among both dermatologists (ICC 0Á95) and rheumatologists (ICC 0Á91). The CLASI damage scores had good inter-rater reliability among dermatologists (ICC 0Á76) and poor inter-rater reliability among rheumatologists (ICC 0Á43). The PGA activity scores had good inter-rater reliability for both dermatologists (ICC 0Á77) and rheumatologists (ICC 0Á73). The PGA damage scores showed moderate inter-rater reliability among both dermatologists (ICC 0Á50) and rheumatologists (ICC 0Á65).
Intrarater reliability
The CLASI intrarater reliability scores are summarized in Table 3 . The CLASI activity scores showed excellent intrarater reliability among both dermatologists (ICC = 0Á995) and rheumatologists (ICC = 0Á96). The CLASI damage scores had excellent intrarater reliability among dermatologists (ICC 0Á87) and good intrarater reliability among rheumatologists (ICC 0Á76).
The PGA activity scores had excellent intrarater reliability for dermatologists (ICC 0Á89) and good intrarater reliability for rheumatologists (ICC 0Á76). The PGA damage scores demonstrated good intrarater reliability among both dermatologists (ICC 0Á76) and rheumatologists (ICC 0Á73).
Construct validity
There were negative associations between the skin PGA activity scores and corresponding CLASI activity scores, as well as between the skin PGA damage scores and corresponding CLASI damage scores. This is because high PGA scores indicate more favourable skin disease, as opposed to high CLASI scores indicating worse skin activity or damage. After adjusting for within-patient and within-physician correlations, the CLASI activity score decreased by 0Á77 (P = 0Á0051) for each unit increase in skin PGA activity. For each unit increase in skin PGA damage, the CLASI damage score decreased by 0Á72 (P = 0Á013).
Physician exit survey questionnaire
Of the six dermatologists, five found the CLASI easier to use than the PGA, and one found the CLASI to be more difficult. Of the six rheumatologists, two found the CLASI easier to use, two found the PGA easier to use, and two had no preference. All 12 physicians found the CLASI to be more appropriate for grading the severity and improvement of CLE skin disease over time. When asked how comfortable they felt using the CLASI vs. the PGA on a scale of 1 to 5 (1 = not comfortable at all, 5 = very comfortable), dermatologists responded with a mean score of 4Á3 vs. 2Á3, and the rheumatologists responded with a mean score of 3Á7 vs. 3Á5.
Discussion
CLE causes significant morbidity, impairment in quality of life and psychological damage to patients. The CLASI was created and previously validated in the adult population to create a standardized outcome tool to assess skin disease activity and damage objectively. This allows physicians and pharmaceutical companies to track clinical efficacy of treatment accurately. 4, 5 However, previous studies in adults may not be generalizable to paediatric CLE, and therefore validation in the paediatric population is critical. Accumulating disease damage from CLE correlates inversely with age of disease onset, 19 producing physical and psychological implications during a formative time in development. In addition, paediatric-onset SLE differs significantly from adult-onset SLE, with a greater frequency of end-organ damage including renal involvement at presentation, a requirement for sustained immunosuppression, and higher overall mortality. [19] [20] [21] [22] The validation of this tool in paediatric CLE will facilitate approval of much-needed paediatric lupus treatments and help to standardize patient care. 5 We conducted the study by recruiting six dermatologists, six rheumatologists and 11 patients with active CLE (Table 1) . Similarly to the results found in the adult population, the CLASI activity score showed excellent inter-rater reliability, 3 compared with the PGA, which showed good inter-rater reliability ( Table 2 ). The inter-rater reliability for CLASI and PGA activity scores were approximately the same for dermatologists as they were for rheumatologists. CLASI inter-rater damage scores were higher in the dermatologist group than in the rheumatologists; the opposite was seen for the PGA, where the rheumatologists had a higher ICC for damage than the dermatologists. However, the activity score is a more important measure than damage because current skin disease activity is measured in clinical trials.
The broad range of scores for our patients, as seen in Figure 2 , as well as the fact that 54 of the 55 CLASI categories were accounted for in our patient population, demonstrates that our study population was diverse and not skewed towards patients with limited activity or damage.
CLASI activity scores showed excellent intrarater reliability for both dermatologists and rheumatologists. In contrast, PGA activity scores showed excellent intrarater reliability among dermatologists, but only good intrarater reliability among rheumatologists. CLASI damage scores showed excellent intrarater reliability, while PGA damage scores showed only good intrarater reliability among dermatologists. Additionally, CLASI and PGA damage scores both showed good intrarater reliability among rheumatologists. These results suggest that overall the CLASI is a more reliable tool than the PGA when considering evaluation by dermatologists and rheumatologists, particularly in the assessment of disease activity for children.
In addition to finding a tool that can be reliable, accurate and sensitive to change, it is also important for the tool to be simple and easy to use. 5, 23 The physician exit surveys showed that the majority of the physicians found the CLASI to be easier to apply than the PGA. Our study had several limitations, including the small sample size of 11 patients. However, despite the small sample size, the inter-and intrarater reliabilities for activity were still excellent, and the results are similar to those achieved in other validation studies. 10, 11, 13, 14 Another limitation is that recall bias may have been introduced during the rerater session, affecting intrarater reliability. There was a short amount of time between the first rating session and the second; however, this recall bias was minimized by not informing the physicians about this rerater session until after they were done completing the first grading session. Additionally, there were a large number of patients evaluated sequentially initially, making recall bias less likely. While we know that our original rating session took approximately 90 min for 12 physicians to grade 11 patients with two sets of tools, we did not have the physicians time each individual session. This limited our ability to compare dermatologists and rheumatologists in regards to efficiency. However, with the information we have, we know that the physicians took about 7Á5 min to score both the CLASI and PGA together. This timing is consistent with the CLASI adult validation study, which had a median time of 5 min for just the CLASI. 1 In conclusion, this study validates the CLASI for use in the paediatric CLE population. The CLASI demonstrated excellent inter-and intrarater reliability for both dermatologists and rheumatologists, and was found to be superior to the PGA scoring system. The majority of physicians also found the CLASI to be an easier tool to use than the PGA. The CLASI could therefore be used in future clinical trials for paediatric patients with CLE. 
